Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies

Cancer Immunology, Immunotherapy

Volumn 58, Issue 3, 2009, Pages 415-427

  Drake, Allison S ^a   Brady, Michael T ^a   Wang, Xin Hui ^b   Sait, Sheila J N ^a   Earp, Justin C ^c   Ghoshal, Sampa ^a   Ferrone, Soldano ^b   Wang, Eunice S ^a,d   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

11q23; Acute leukemia; HMW MAA; Immunotherapy

Indexed keywords

CYTARABINE; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225.28; MONOCLONAL ANTIBODY 763.74; MONOCLONAL ANTIBODY VT68.2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA; MELANOMA; MICE; MICE, SCID; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION;

EID: 58149305549     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0567-5     Document Type: Article

References (50)

1. CH Pui PS Gaynon JM Boyett JM Chessells A Baruchel W Kamps LB Silverman A Biondi DO Harms E Vilmer M Schrappe B Camitta 2002 Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region Lancet 359 1909 1915
2. JC Byrd K Mrozek RK Dodge AJ Carroll CG Edwards DC Arthur MJ Pettenati SR Patil KW Rao MS Watson PR Koduru JO Moore RM Stone RJ Mayer EJ Feldman FR Davey CA Schiffer RA Larson CD Bloomfield 2002 Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 4325 4336
3. N Gokbuget D Hoelzer 2004 Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects Ann Hematol 83 201 205
4. FG Behm FO Smith SC Raimondi CH Pui ID Bernstein 1996 Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements Blood 87 1134 1139
5. FO Smith C Rauch DE Williams CJ March D Arthur J Hilden BC Lampkin JD Buckley CV Buckley WG Woods PA Dinndorf P Sorensen J Kersey D Hammond ID Bernstein 1996 The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23 Blood 87 1123 1133
6. JM Hilden FO Smith JL Frestedt R McGlennen WB Howells PH Sorensen DC Arthur WG Woods J Buckley ID Bernstein JH Kersey 1997 MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia Blood 89 3801 3805
7. L Mauvieux E Delabesse P Bourquelot I Radford-Weiss A Bennaceur G Flandrin F Valensi EA MacIntyre 1999 NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases Br J Haematol 107 674 676
8. C Wuchter J Harbott C Schoch S Schnittger A Borkhardt L Karawajew R Ratei V Ruppert T Haferlach U Creutzig B Dorken WD Ludwig 2000 Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 Leukemia 14 1232 1238
9. A Borkhardt C Wuchter S Viehmann S Pils A Teigler-Schlegel M Stanulla M Zimmermann WD Ludwig G Janka-Schaub M Schrappe J Harbott 2002 Infant acute lymphoblastic leukemia-combined cytogenetic, immunophenotypical and molecular analysis of 77 cases Leukemia 16 1685 1690
10. S Schwartz H Rieder B Schlager T Burmeister L Fischer E Thiel 2003 Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65 s(+)/CD15(+) B-cell phenotype Leukemia 17 1589 1595
11. A Mittelman ZJ Chen H Yang GY Wong S Ferrone 1992 Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci USA 89 466 470
12. A Mittelman ZJ Chen CC Liu S Hirai S Ferrone 1994 Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23 Cancer Res 54 415 421
13. H Bender M Grapow A Schomburg U Reinhold HJ Biersack 1997 Effects of diagnostic application of monoclonal antibody on survival in melanoma patients Hybridoma 16 65 68
14. C Hafner H Breiteneder S Ferrone C Thallinger S Wagner WM Schmidt J Jasinska M Kundi K Wolff CC Zielinski O Scheiner U Wiedermann H Pehamberger 2005 Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody Int J Cancer 114 426 432
15. J Yang MA Price CL Neudauer C Wilson S Ferrone H Xia J Iida MA Simpson JB McCarthy 2004 Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms J Cell Biol 165 881 891
16. Z Xia SN Sait MR Baer M Barcos KA Donohue D Lawrence LA Ford AM Block H Baumann M Wetzler 2001 Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia Leuk Res 25 473 482
17. CJ Barnstable WF Bodmer G Brown G Galfre C Milstein AF Williams A Ziegler 1978 Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis Cell 14 9 20
18. BS Wilson K Imai PG Natali S Ferrone 1981 Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies Int J Cancer 28 293 300
19. 1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen Cell Immunol 72 239 247
20. M Tsujisaki K Sakaguchi M Igarashi P Richiardi F Perosa S Ferrone 1988 Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1 Transplantation 45 632 639
21. M Kusama T Kageshita ZJ Chen S Ferrone 1989 Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies J Immunol 143 3844 3852
22. M Temponi AM Gold S Ferrone 1992 Binding parameters and idiotypic profile of the whole immunoglobulin and Fab′ fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen Cancer Res 52 2497 2503
23. M Wetzler MR Baer SJ Stewart K Donohue L Ford CC Stewart EA Repasky S Ferrone 2001 HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse Leukemia 15 128 133
24. M Wetzler MT Brady E Tracy ZR Li KA Donohue KL O'Loughlin Y Cheng A Mortazavi AA McDonald P Kunapuli PK Wallace MR Baer JK Cowell H Baumann 2006 Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation Clin Cancer Res 12 6817 6825
25. MR Campoli CC Chang T Kageshita X Wang JB McCarthy S Ferrone 2004 Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance Crit Rev Immunol 24 267 296
26. AV Hill 1910 The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves J Physiol 40 iv vii
27. LM Levasseur H Faessel HK Slocum WR Greco 1998 Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay J Pharmacokinet Biopharm 26 717 733
28. EJ Ariens JM Van Rossum AM Simonis 1957 Affinity, intrinsic activity and drug interactions Pharmacol Rev 9 218 236
29. EJ Ariens 1954 Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory Arch Int Pharmacodyn Ther 99 32 49
30. D'Argenio DZ, Schumitzky A (1997) ADAPT II users guide: pharmacokinetc/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
31. ES Wang J Teruya-Feldstein Y Wu Z Zhu DJ Hicklin MA Moore 2004 Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo Blood 104 2893 2902
32. R Lumkul NC Gorin MT Malehorn GT Hoehn R Zheng B Baldwin D Small S Gore D Smith PS Meltzer CI Civin 2002 Human AML cells in NOD/SCID mice: engraftment potential and gene expression Leukemia 16 1818 1826
33. J Lee SN Sait M Wetzler 2004 Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts Int Immunol 16 1377 1389
34. G Ragupathi NX Liu C Musselli S Powell K Lloyd PO Livingston 2005 Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity J Immunol 174 5706 5712
35. S Wagner C Hafner D Allwardt J Jasinska S Ferrone CC Zielinski O Scheiner U Wiedermann H Pehamberger H Breiteneder 2005 Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro J Immunol 174 976 982
36. SA Desai X Wang EJ Noronha T Kageshita S Ferrone 1998 Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library Cancer Res 58 2417 2425
37. A Moore Z Medarova A Potthast G Dai 2004 In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe Cancer Res 64 1821 1827
38. T Kageshita T Nakamura M Yamada N Kuriya T Arao S Ferrone 1991 Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions Cancer Res 51 1726 1732
39. DJ Ruiter RO Schlingemann JR Westphal M Denijn FJ Rietveld RM De Waal 1993 Angiogenesis in wound healing and tumor metastasis Behring Inst Mitt 92 258 272
40. A Perez-Atayde S Sallan U Tedrow S Connors E Allred J Folkman 1997 Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 815 821
41. KJ Hatfield AM Olsnes BT Gjertsen O Bruserud 2005 Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies Curr Cancer Drug Targets 5 229 248
42. F Giles E Estey S O'Brien 2003 Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia Cancer 98 2095 2104
43. CC Chang M Campoli W Luo W Zhao KS Zaenker S Ferrone 2004 Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms Ann NY Acad Sci 1028 340 350
44. S Hehlgans M Haase N Cordes 2007 Signalling via integrins: implications for cell survival and anticancer strategies Biochim Biophys Acta 1775 163 180
45. J Iida AM Meijne TR Oegema Jr TA Yednock NL Kovach LT Furcht JB McCarthy 1998 A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion J Biol Chem 273 5955 5962
46. IH Gelman 2003 Pyk 2 FAKs, any two FAKs Cell Biol Int 27 507 510
47. EJ Feldman J Brandwein R Stone M Kalaycio J Moore J O'Connor N Wedel GJ Roboz C Miller R Chopra JC Jurcic R Brown WC Ehmann P Schulman SR Frankel D De Angelo D Scheinberg 2005 Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia J Clin Oncol 23 4110 4116
48. PP Piccaluga G Martinelli M Rondoni M Malagola S Gaitani G Visani M Baccarani 2004 First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients Leuk Res 28 987 990
49. JG Jurcic T DeBlasio L Dumont T-J Yao DA Scheinberg 2000 Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia Clin Cancer Res 6 372 380
50. MJ Smyth GP Dunn RD Schreiber 2006 Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 90 1 50